Encore Medical now private:
This article was originally published in Clinica
Encore Medical's shares have ceased trading on Nasdaq after the company completed a buy-out backed by private equity group Blackstone Capital Partners. The $887m transaction, announced in June (see Clinica No 1213, p 15), was approved on November 2 at a special meeting of stockholders, who will receive $6.55 cash per share of common stock held. The deal was financed by equity contributed by Blackstone, cash on hand, credit facilities and new notes. Blackstone director Chinh Chu becomes chairman of the Austin, Texas-based orthopaedic device maker.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.